Vertex Pharmaceuticals is shifting its investment strategy to focus on opportunities in cystic fibrosis, according to Ian Smith, chief financial officer, who spoke at the Credit Suisse 2013 Healthcare Conference in mid November.
Vertex Pharmaceuticals is shifting its investment strategy to focus on opportunities in cystic fibrosis, according to Ian Smith, chief financial officer, who spoke at the Credit Suisse 2013 Healthcare Conference in mid November.
A few weeks earlier, Vertex Pharmaceuticals announced a 15% workforce reduction associated with support of its hepatitis C drug telaprevir (Incivik) because new medicines for this therapeutic area are nearing approval. The company restructuring was necessary to lower operating expenses, with an expected 2014 savings of $150 million to $250 million, Smith explained.
Over the next 3 to 6 months, Vertex expects to review monotherapy data from two phase 3 studies for ivacaftor (Kalydeco), a drug already FDA-approved for cystic fibrosis patients with the G551D mutation in the CFTR gene, which accounts for 4% to 5% of cases of cystic fibrosis. Vertex hopes to expand its ivacaftor label to include cystic fibrosis patients with the R117H-CFTR mutation and pediatric patients ages 2 through 5 years with CFTR gating mutation.
“All this data would potentially increase the patient population to treat from 2,000 to 7,000 patients,” Smith noted.
Vertex also is investigating combination therapy of ivacaftor with lumacaftor in an ongoing 2 phase 3 studies of patients 12 years and older with cystic fibrosis who are homozygous for the F508del mutation. “We should have the data by the middle of next year,” he said. “This would significantly open up the number of patients that we may be able to treat. This would open up the patient population to another 28,000 patients worldwide.”
Vertex is continuing R&D efforts in areas of oncology, oral therapies for hepatitis C, and other areas as well, Smith said.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More